Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Reviewing interim Phase 1 clinical results for JANX007 in metastatic castration-resistant prostate cancer (mCRPC)

Ticker(s): JANX

Who's the expert?

A medical oncologist specializing in advanced prostate cancer with experience treating mCRPC across systemic therapies including ARPIs, taxanes, radioligand therapies, and emerging immune-engaging modalities. Ideally, the expert has familiarity with PSMA-targeted therapies and early-phase immunotherapy trial design, including interpretation of response rates, PSA kinetics, and tolerability signals in first-in-human studies.

Interview Goal

The goal of the interview is to analyze the updated interim Phase 1 clinical results for JANX007, a PSMA-directed Tumor Activated T-Cell Engager (TRACTr), in patients with metastatic castration-resistant prostate cancer. The discussion will focus on response durability, PSA decline patterns, safety profile including CRS management, the impact of transitioning to every-two-week dosing, and the potential implications for earlier-line treatment and combination strategies as the program advances.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here To Join
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

378Days Left to Join Project

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here To Join
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.